On May 20, 2025, Viking Therapeutics, Inc. held its Annual Meeting where stockholders voted to elect two directors and ratified the accounting firm for the fiscal year 2025, with 68.3% of shares represented. Notable votes included 28,050,978 for Matthew W. Foehr and approval of executive compensation with 29,265,273 votes in favor.